ANI Pharma reports positive 6-month Phase 4 SYNCHRONICITY data for ILUVIEN in chronic non-infectious uveitis

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

ANIP

0.00
  • ANI Pharmaceuticals reported positive six-month topline Phase 4 SYNCHRONICITY data for ILUVIEN in chronic non-infectious posterior segment uveitis.
  • Trial met both co-primary endpoints at month 6: BCVA improved 3.6 ETDRS letters (p≤0.0077); CST fell 157.5 microns (p<0.0001).
  • In the safety population, 29% had treatment-related adverse events; most common were ocular hypertension 6% and cataract 5%.
  • IOP rose to ≥25 mmHg in 18% of patients; 7% required laser or surgical IOP-lowering intervention.
  • Detailed results are scheduled for presentation at medical conferences in 4Q 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130650PRIMZONEFULLFEED9760815) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.